TWiV 880: COVID-19 clinical update #107 with Dr. Daniel Griffin

March 26, 2022

In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia.

Click arrow to play
Download TWiV 880 (57 MB .mp3, 48 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

5 comments on “TWiV 880: COVID-19 clinical update #107 with Dr. Daniel Griffin

  1. I did not see the step by step drug treatment protocol that Dr. Daniel Griffin recommends in the show notes. Please post it would be helpful.
    Thank you,

    • Patrick Mar 30, 2022

      Came here today looking for the same thing.

    • Charles Mar 31, 2022

      I am also came here looking for the step-by-step drug treatment protocol. Please post each week and update as needed.

      I did write down the first week drug treatments ranked in order of his preference (apologies in advance for misspellings) as of this particular show:

      1. Paxlovid
      2. Bebtelovimab
      3. Remdesivir
      4. Malnupirivir

  2. A. Stoll Mar 27, 2022

    Hi there,
    How should one interpret and respond to the statement below in layman’s terms?
    A very short reply would be much appreciated!
    Best regards,
    Andrew Stoll

    “The bodies of the vaccinated definitely do serve as excellent selection grounds for vaccine-escaping variants because the vaccines do not inhibit viral growth in the nasopharynx and do not inhibit initial infection. (In fact, it is clear that the vaccines actually promote infection in all but those boosted less than about 8 weeks previously.) The bodies of the vaccinated also have immune systems that are focussed on the spike protein rather than the rest of entire virus (and due to “original antigenic sin” a vaccinated person then does not make strong subsequent antibody responses to the rest of the virus if they become infected). Those who become immune through infection (rather than vaccination) have broader antibody responses that make it more difficult for the virus to evolve to escape those.”